Big news. The ground has shifted as Warner Bros. Discovery said its board determined tha a new proposal from Paramount could reasonably be expected to lead to a so-called “Company Superior Proposal” as defined in WBD’s merger agreement with Netflix and that it will continue talks with the David Ellison company. The revised proposal includes an increased purchase price of $31.00 per WBD share in cash, plus a daily ticking fee equal to $0.25 per quarter beginning after September 30, 2026, as well as a $7 bil ...

Core Insights - Kenvue exceeded Wall Street estimates for its fourth-quarter results and announced a global workforce reduction as it moves towards a planned acquisition by Kimberly-Clark [1] Financial Performance - Kenvue's fourth-quarter net sales increased by 3.2% to $3.78 billion, surpassing analysts' consensus of $3.68 billion [1] - The self-care segment, which includes brands like Tylenol and Benadryl, reported a 1.5% increase in net sales to $1.59 billion, exceeding estimates of $1.52 billion [1] - The essential health unit, housing brands such as Listerine and Band-Aid, achieved net sales of $1.15 billion, a 6.1% year-over-year rise, compared to the average estimate of $1.12 billion [1] - Kenvue posted a quarterly adjusted profit of 27 cents per share, while analysts had estimated 22 cents per share [1] Workforce Reduction - Kenvue's board approved a plan to optimize its operating model, resulting in a net reduction of approximately 3.5% of its global workforce, which was about 22,000 employees last year [1] - The planned job cuts are expected to incur pre-tax restructuring expenses and other charges totaling around $250 million in 2026 [1] Acquisition Plans - Kimberly-Clark proposed to acquire Kenvue for over $40 billion to create a global consumer health company, with the merger expected to close in the second half of 2026 [1]

Core Viewpoint - Cerity Partners is merging with Verus Investments to enhance its institutional capabilities, significantly expanding its presence in the institutional advisory space [1]. Company Overview - Cerity Partners is a large registered investment advisory firm based in New York City [1]. - Verus Investments is an institutional advisor that oversees $1.2 trillion in assets [1]. Strategic Implications - The merger indicates Cerity's strategic move to strengthen its institutional advisory services [1]. - This deal positions Cerity to better serve institutional clients by leveraging Verus's extensive asset management experience [1].

Core Insights - Monteverde & Associates PC is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and has successfully recovered millions for shareholders [1] - The firm is currently investigating multiple companies related to their proposed sales, including The Brand House Collective, Avidity Biosciences, NorthWestern Energy Group, and Two Harbors Investment Corp [1][2][3][4] Company Investigations - The Brand House Collective, Inc. (NASDAQ: TBHC) is set to be sold to Bed Bath & Beyond, Inc., with shareholders expected to receive 0.1993 shares of Bed Bath & Beyond for each share of Brand House [1] - Avidity Biosciences, Inc. (NASDAQ: RNA) is proposed to be sold to Novartis AG, with shareholders receiving $72.00 per share in cash [2] - NorthWestern Energy Group, Inc. (NASDAQ: NWE) is being sold to Black Hills Corp, where shareholders will receive 0.98 shares of Black Hills for each share of NorthWestern, resulting in approximately 44% ownership of the combined company for NorthWestern shareholders [3] - Two Harbors Investment Corp. (NYSE: TWO) is proposed to be sold to UWM Holdings Corporation, with shareholders receiving 2.3328 shares of UWM Class A common stock for each share of Two Harbors [4] Shareholder Votes - The shareholder vote for The Brand House Collective is scheduled for March 17, 2026 [2] - The shareholder vote for Avidity Biosciences is scheduled for February 23, 2026 [3] - The shareholder vote for NorthWestern Energy Group is scheduled for April 2, 2026 [4]

The AI IPO race is officially on and it's approaching zero hour. Open AAI reportedly targeting a Wall Street debut for the fourth quarter of this year. The Wall Street Journal says the valuation of the AI startup Phenom could hit $830 billion.The timing of OpenAI's IPO plans may have been fast-tracked because its rival Anthropic is also planning an endofear IPO. The Amazon and Google backed AI company founded by former Open AI leaders projects it will break even by 2028. That would be two years ahead of ope ...

36氪获悉，中金公司公告，公司与东兴证券、信达证券正在筹划由中金公司通过换股方式吸收合并东兴 证券、信达证券。综上，中金公司的A股换股价格为36.91元/股，东兴证券的A股换股价格为16.14元/ 股，信达证券的A股换股价格为19.15元/股。根据上述公式，东兴证券与中金公司的换股比例为 1:0.4373，即每1股东兴证券A股股票可以换得0.4373股中金公司A股股票；信达证券与中金公司的换股 比例为1:0.5188，即每1股信达证券A股股票可以换得0.5188股中金公司A股股票。 ...

Core Insights - CPKC has successfully integrated Kansas City Southern since the acquisition in 2021, focusing on growth and operational efficiency [3] - The company has achieved a 5% increase in volumes on a Revenue Ton Mile (RTM) basis this year, demonstrating strong performance in the industry [3] - CPKC is expected to report double-digit Earnings Per Share (EPS) growth for both the previous and current year, indicating robust financial health [4] - The company has maintained its position as an industry leader in safety, with improvements in train accident frequency and personal injury metrics [4]

November 19, 2025 04:12 PM GMT China International Capital Corp. Ltd. | Asia Pacific Proposed Merger Could Strengthen Wealth Management Franchise and Capital Base Key Takeaways Cinda and Dongxing's smaller size and complementary business mix are opportunities to extract synergy. Combined, the two brokers's total assets were ~Rmb244bn as of September 2025 vs. CICC at Rmb765bn. The two brokers are focused primarily on retail brokerage, with ~35% of revenue from brokerage fees and margin interests and ~50% rev ...

Core Insights - The article discusses the qualifications and expertise of Max Greve, highlighting his educational background and areas of writing focus [1] Group 1 - Max Greve graduated from Northwestern University with a quadruple major in History, Economics, Political Science, and International Studies [1] - He is a full-time writer who covers stock market trends, government, current events, macroeconomic trends, and inefficiencies in professional sports [1]

Core Points - Enzon Pharmaceuticals and Viskase Companies have amended their merger agreement, with Viskase merging into a subsidiary of Enzon in an all-stock transaction, resulting in Viskase stockholders owning 55% and Enzon stockholders owning 45% of the combined company [1][2][7] Summary by Sections Merger Agreement - The amendment reflects recent operational developments at Viskase and its expected near-term operations [1] - The merger will maintain Enzon's net operating losses and other tax benefits for the combined company [3] - The amendment was approved by the independent directors of both companies and their respective Boards of Directors [4] Financial Adjustments - The exchange ratio for Viskase stockholders has been adjusted so they will own 55% of the combined company [7] - Enzon will conduct a 1 for 100 reverse stock split prior to the merger [7] - The minimum cash requirement for Enzon at the closing of the merger has been reduced [7] Company Profiles - Enzon Pharmaceuticals is positioned as a public company acquisition vehicle, aiming to become an acquisition platform [5] - Viskase Companies produces non-edible casings for processed meat products and operates nine manufacturing facilities globally, selling products in nearly one hundred countries [8]